Stock Analysis

Industry Analysts Just Made A Meaningful Upgrade To Their Al-Dawaa Medical Services Company (TADAWUL:4163) Revenue Forecasts

Al-Dawaa Medical Services Company (TADAWUL:4163) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The revenue forecast for this year has experienced a facelift, with the analysts now much more optimistic on its sales pipeline. Investor sentiment seems to be improving too, with the share price up 4.7% to ر.س79.90 over the past 7 days. It will be interesting to see if this latest upgrade is enough to kickstart further buying interest in the stock.

Following the upgrade, the current consensus from Al-Dawaa Medical Services' five analysts is for revenues of ر.س7.7b in 2025 which - if met - would reflect a decent 20% increase on its sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of ر.س7.0b in 2025. It looks like there's been a clear increase in optimism around Al-Dawaa Medical Services, given the decent improvement in revenue forecasts.

View our latest analysis for Al-Dawaa Medical Services

earnings-and-revenue-growth
SASE:4163 Earnings and Revenue Growth April 16th 2025

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's clear from the latest estimates that Al-Dawaa Medical Services' rate of growth is expected to accelerate meaningfully, with the forecast 20% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 7.4% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 7.4% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Al-Dawaa Medical Services is expected to grow much faster than its industry.

Advertisement

The Bottom Line

The highlight for us was that analysts increased their revenue forecasts for Al-Dawaa Medical Services this year. Analysts also expect revenues to grow faster than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Al-Dawaa Medical Services.

Want to learn more? We have analyst estimates for Al-Dawaa Medical Services going out to 2027, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SASE:4163

Al-Dawaa Medical Services

Primarily operates as a pharmaceutical retail company in the Kingdom of Saudi Arabia and Kingdom of Bahrain.

Flawless balance sheet and undervalued.

Advertisement

Weekly Picks

AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25367.6% overvalued
68 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
65 users have followed this narrative
10 users have commented on this narrative
19 users have liked this narrative
FU
FundamentallySarcastic
CCP logo
FundamentallySarcastic on Credit Corp Group ·

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08

Fair Value:AU$12.6410.4% overvalued
11 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Updated Narratives

BO
MU logo
BonSquid88 on Micron Technology ·

Micron Technology will experience a robust 16.5% revenue growth

Fair Value:US$40021.1% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MA
AMZN logo
MarketMuse on Amazon.com ·

Amazon will rebound as AI investments start paying off by late 2026

Fair Value:US$45049.7% undervalued
45 users have followed this narrative
2 users have commented on this narrative
0 users have liked this narrative
RO
Robbo
HVN logo
Robbo on Harvey Norman Holdings ·

Inside Harvey Norman: Asset-Heavy Retail in an Online World

Fair Value:AU$5.8419.5% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
65 users have followed this narrative
10 users have commented on this narrative
19 users have liked this narrative
AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25367.6% overvalued
68 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0225.4% undervalued
1011 users have followed this narrative
6 users have commented on this narrative
28 users have liked this narrative